Compare Cronos Group Inc (CRON) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Sana Biotechnology Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Cronos Group Inc is the larger of the two by market cap, and Cronos Group Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Sana Biotechnology Inc for 23 Days on average.
| CRON | SANA | |
|---|---|---|
Market Cap | $1.18B | $836.71M |
Volume | 968,037 | 4,507,444 |
Sector | Health | Health |
52-Week High | $3.55 | $5.92 |
52-Week Low | $2.30 | $2.68 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $387.62M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, amid a bearish technical signal. The stock shows mixed earnings history, with recent beats in Q1 and Q2 2026 but a miss in Q4 2025. Revenue growth is robust, increasing from $118M in 2024 to $147M in 2025, with a projected rise to $179M in 2026. However, profitability remains volatile, with a net loss of $9.45M in 2025 despite a strong gross margin of 45.86%. Recent news highlights the company's Investor Day focusing on global expansion and cash flow generation.
The outlook for CRON is cautiously optimistic, driven by international growth and a debt-free balance sheet with $827M in cash. Key risks include ongoing profitability challenges, competitive pressures, and regulatory uncertainties in the cannabis sector. Analyst sentiment is mixed, with 60% hold ratings, suggesting a wait-and-see approach. Investors should weigh strong revenue trends against execution risks and margin volatility.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative earnings, and substantial cash burn. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral conditions. Recent earnings have been mixed with two misses and one beat against expectations, while analyst sentiment remains overwhelmingly positive with 82% buy ratings.
The outlook hinges on SANA's clinical pipeline success and future revenue generation capabilities. Investment opportunity exists in the company's promising biotechnology platform and strong analyst support, but risks include continued cash burn, lack of current revenue, and execution challenges in bringing therapies to market. The stock represents a high-risk, high-reward biotechnology investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
